These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11115849)

  • 1. Caveolin-3 deficiency causes muscle degeneration in mice.
    Hagiwara Y; Sasaoka T; Araishi K; Imamura M; Yorifuji H; Nonaka I; Ozawa E; Kikuchi T
    Hum Mol Genet; 2000 Dec; 9(20):3047-54. PubMed ID: 11115849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolae and caveolin-3 in muscular dystrophy.
    Galbiati F; Razani B; Lisanti MP
    Trends Mol Med; 2001 Oct; 7(10):435-41. PubMed ID: 11597517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.
    Smythe GM; Eby JC; Disatnik MH; Rando TA
    J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.
    Volonte D; Peoples AJ; Galbiati F
    Mol Biol Cell; 2003 Oct; 14(10):4075-88. PubMed ID: 14517320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy.
    Herrmann R; Straub V; Blank M; Kutzick C; Franke N; Jacob EN; Lenard HG; Kröger S; Voit T
    Hum Mol Genet; 2000 Sep; 9(15):2335-40. PubMed ID: 11001938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype.
    Aravamudan B; Volonte D; Ramani R; Gursoy E; Lisanti MP; London B; Galbiati F
    Hum Mol Genet; 2003 Nov; 12(21):2777-88. PubMed ID: 12966035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency.
    Minetti C; Bado M; Broda P; Sotgia F; Bruno C; Galbiati F; Volonte D; Lucania G; Pavan A; Bonilla E; Lisanti MP; Cordone G
    Am J Pathol; 2002 Jan; 160(1):265-70. PubMed ID: 11786420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle.
    Matsuda C; Hayashi YK; Ogawa M; Aoki M; Murayama K; Nishino I; Nonaka I; Arahata K; Brown RH
    Hum Mol Genet; 2001 Aug; 10(17):1761-6. PubMed ID: 11532985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities.
    Galbiati F; Engelman JA; Volonte D; Zhang XL; Minetti C; Li M; Hou H; Kneitz B; Edelmann W; Lisanti MP
    J Biol Chem; 2001 Jun; 276(24):21425-33. PubMed ID: 11259414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caveolin and NOS in the Development of Muscular Dystrophy.
    Nakashima M; Suga N; Yoshikawa S; Matsuda S
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity.
    Sunada Y; Ohi H; Hase A; Ohi H; Hosono T; Arata S; Higuchi S; Matsumura K; Shimizu T
    Hum Mol Genet; 2001 Feb; 10(3):173-8. PubMed ID: 11159934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.
    Galbiati F; Volonte D; Minetti C; Chu JB; Lisanti MP
    J Biol Chem; 1999 Sep; 274(36):25632-41. PubMed ID: 10464299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy.
    Minetti C; Sotgia F; Bruno C; Scartezzini P; Broda P; Bado M; Masetti E; Mazzocco M; Egeo A; Donati MA; Volonte D; Galbiati F; Cordone G; Bricarelli FD; Lisanti MP; Zara F
    Nat Genet; 1998 Apr; 18(4):365-8. PubMed ID: 9537420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable reduction of caveolin-3 in patients with LGMD2B/MM.
    Walter MC; Braun C; Vorgerd M; Poppe M; Thirion C; Schmidt C; Schreiber H; Knirsch UI; Brummer D; Müller-Felber W; Pongratz D; Müller-Höcker J; Huebner A; Lochmüller H
    J Neurol; 2003 Dec; 250(12):1431-8. PubMed ID: 14673575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency.
    Ho M; Post CM; Donahue LR; Lidov HG; Bronson RT; Goolsby H; Watkins SC; Cox GA; Brown RH
    Hum Mol Genet; 2004 Sep; 13(18):1999-2010. PubMed ID: 15254015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases.
    Sotgia F; Bonuccelli G; Minetti C; Woodman SE; Capozza F; Kemp RG; Scherer PE; Lisanti MP
    Am J Pathol; 2003 Dec; 163(6):2619-34. PubMed ID: 14633633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease.
    Sotgia F; Woodman SE; Bonuccelli G; Capozza F; Minetti C; Scherer PE; Lisanti MP
    Am J Physiol Cell Physiol; 2003 Nov; 285(5):C1150-60. PubMed ID: 12839838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy.
    Hayashi YK; Matsuda C; Ogawa M; Goto K; Tominaga K; Mitsuhashi S; Park YE; Nonaka I; Hino-Fukuyo N; Haginoya K; Sugano H; Nishino I
    J Clin Invest; 2009 Sep; 119(9):2623-33. PubMed ID: 19726876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.
    Galbiati F; Volonte D; Minetti C; Bregman DB; Lisanti MP
    J Biol Chem; 2000 Dec; 275(48):37702-11. PubMed ID: 10973975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two novel CAV3 gene mutations in Japanese families.
    Sugie K; Murayama K; Noguchi S; Murakami N; Mochizuki M; Hayashi YK; Nonaka I; Nishino I
    Neuromuscul Disord; 2004 Dec; 14(12):810-4. PubMed ID: 15564037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.